NYSEAMERICAN:HEB - Hemispherx BioPharma Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.18 0.00 (0.00 %)
(As of 03/20/2019 04:00 PM ET)
Previous Close$0.1719
Today's Range$0.17 - $0.18
52-Week Range$0.15 - $0.51
Volume537,506 shs
Average Volume488,259 shs
Market Capitalization$8.56 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Hemispherx Biopharma, Inc., a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of CFS, Hepatitis B, HIV, and cancer patients with renal cell carcinoma and malignant melanoma. The company was founded in 1990 and is headquartered in Orlando, Florida.

Receive HEB News and Ratings via Email

Sign-up to receive the latest news and ratings for HEB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:HEB
CUSIPN/A
Phone+1-407-2718516

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$8.56 million
Next Earnings Date4/1/2019 (Estimated)
OptionableNot Optionable

Hemispherx BioPharma (NYSEAMERICAN:HEB) Frequently Asked Questions

What is Hemispherx BioPharma's stock symbol?

Hemispherx BioPharma trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "HEB."

How were Hemispherx BioPharma's earnings last quarter?

Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB) announced its quarterly earnings data on Wednesday, November, 15th. The specialty pharmaceutical company reported ($0.04) EPS for the quarter. The specialty pharmaceutical company earned $0.09 million during the quarter. View Hemispherx BioPharma's Earnings History.

When is Hemispherx BioPharma's next earnings date?

Hemispherx BioPharma is scheduled to release their next quarterly earnings announcement on Monday, April 1st 2019. View Earnings Estimates for Hemispherx BioPharma.

Has Hemispherx BioPharma been receiving favorable news coverage?

News stories about HEB stock have been trending positive on Wednesday, InfoTrie reports. InfoTrie rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Hemispherx BioPharma earned a coverage optimism score of 2.4 on InfoTrie's scale. They also gave news coverage about the specialty pharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the immediate future.

Are investors shorting Hemispherx BioPharma?

Hemispherx BioPharma saw a increase in short interest in the month of February. As of February 28th, there was short interest totalling 755,672 shares, an increase of 8.9% from the February 15th total of 693,908 shares. Based on an average daily volume of 686,913 shares, the short-interest ratio is currently 1.1 days. Approximately 1.6% of the company's stock are short sold. View Hemispherx BioPharma's Current Options Chain.

Who are some of Hemispherx BioPharma's key competitors?

What other stocks do shareholders of Hemispherx BioPharma own?

Who are Hemispherx BioPharma's key executives?

Hemispherx BioPharma's management team includes the folowing people:
  • Mr. Thomas K. Equels, Exec. Vice Chairman, CEO & Pres (Age 66)
  • Mr. Adam Pascale, CFO & Chief Accounting Officer (Age 71)
  • Mr. Peter W. Rodino III, J.D., Exec. Director of Gov.al Relations, Gen. Counsel & Sec. (Age 68)
  • Mr. Wayne S. Springate, Sr. VP of Operations (Age 48)
  • Dr. David R. Strayer, Chief Scientific Officer & Medical Director (Age 73)

How do I buy shares of Hemispherx BioPharma?

Shares of HEB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Hemispherx BioPharma's stock price today?

One share of HEB stock can currently be purchased for approximately $0.1750.

How big of a company is Hemispherx BioPharma?

Hemispherx BioPharma has a market capitalization of $8.56 million.

What is Hemispherx BioPharma's official website?

The official website for Hemispherx BioPharma is http://www.hemispherx.net/.

How can I contact Hemispherx BioPharma?

Hemispherx BioPharma's mailing address is 860 N Orange Ave Ste B, ORLANDO, FL 32801-5205, United States. The specialty pharmaceutical company can be reached via phone at +1-407-2718516.


MarketBeat Community Rating for Hemispherx BioPharma (NYSEAMERICAN HEB)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  177 (Vote Outperform)
Underperform Votes:  208 (Vote Underperform)
Total Votes:  385
MarketBeat's community ratings are surveys of what our community members think about Hemispherx BioPharma and other stocks. Vote "Outperform" if you believe HEB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HEB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel